NCT00676377

Brief Summary

Postoperative ileus (POI) in the absence of any mechanical obstruction remains a commonly encountered clinical problem.So, this study aimed to show the effective way to decrease the rate of postoperative Ileus (POI).

Trial Health

87
On Track

Trial Health Score

Automated assessment based on enrollment pace, timeline, and geographic reach

Enrollment
3

participants targeted

Target at below P25 for phase_4

Timeline
Completed

Started Aug 2007

Shorter than P25 for phase_4

Geographic Reach
1 country

1 active site

Status
completed

Health score is calculated from publicly available data and should be used for screening purposes only.

Trial Relationships

Click on a node to explore related trials.

Study Timeline

Key milestones and dates

Study Start

First participant enrolled

August 1, 2007

Completed
4 months until next milestone

Primary Completion

Last participant's last visit for primary outcome

December 1, 2007

Completed
2 months until next milestone

Study Completion

Last participant's last visit for all outcomes

February 1, 2008

Completed
3 months until next milestone

First Submitted

Initial submission to the registry

May 12, 2008

Completed
1 day until next milestone

First Posted

Study publicly available on registry

May 13, 2008

Completed
Last Updated

May 13, 2008

Status Verified

May 1, 2008

Enrollment Period

4 months

First QC Date

May 12, 2008

Last Update Submit

May 12, 2008

Conditions

Keywords

Neostigmine, Post Operative, Ileus

Outcome Measures

Primary Outcomes (1)

  • show the effective way to decrease the rate of postoperative Ileus (POI).

    6 hours

Secondary Outcomes (1)

  • abdominal circumference, colonic diameters, and clinical response were again measured.

    3 hours

Study Arms (2)

1

EXPERIMENTAL

Neostigmine

Drug: Neostigmine

2

PLACEBO COMPARATOR

Placebo

Drug: Saline

Interventions

2.5 mg of neostigmine intravenously in 250 ml normal saline over a period of thirty minutes ,Half Life 3 Hours

Also known as: Neostigmine Group
1
SalineDRUG

Saline Placebo

Also known as: Placebo Group
2

Eligibility Criteria

Age18 Years - 76 Years
Sexall
Healthy VolunteersNo
Age GroupsAdult (18-64), Older Adult (65+)

You may qualify if:

  • Patients with acute colonic pseudo-obstruction who were 18 years of age or older
  • Patients had to have a cecal diameter of at least 10 cm on plain radiographs
  • Mechanical obstruction was ruled out by the finding of air throughout all colonic segments including the rectosigmoid on plain abdominal radiographs

You may not qualify if:

  • With peritoneal signs on physical examination or free air on radiographs; active bronchospasm requiring medication
  • Treatment with prokinetic drugs such as cisapride or metoclopramide in the 24 hours before evaluation
  • A history of colon cancer or partial colonic resection
  • Active gastrointestinal bleeding
  • Pregnancy
  • Positive history of Myocardial Infarction, Intestinal Resection or a serum creatinine concentration of more than 3 mg per deciliter (265 µmol per liter)

Contact the study team to confirm eligibility.

Sponsors & Collaborators

Study Sites (1)

Baqyiattalah University of Medical Science

Tehran, Iran

Location

Related Publications (1)

  • Ponec RJ, Saunders MD, Kimmey MB. Neostigmine for the treatment of acute colonic pseudo-obstruction. N Engl J Med. 1999 Jul 15;341(3):137-41. doi: 10.1056/NEJM199907153410301.

MeSH Terms

Conditions

Ileus

Interventions

NeostigmineSodium Chloride

Condition Hierarchy (Ancestors)

Intestinal ObstructionIntestinal DiseasesGastrointestinal DiseasesDigestive System Diseases

Intervention Hierarchy (Ancestors)

Phenylammonium CompoundsQuaternary Ammonium CompoundsAminesOrganic ChemicalsOnium CompoundsChloridesHydrochloric AcidChlorine CompoundsInorganic ChemicalsSodium Compounds

Study Officials

  • S.Ahmad Fanaei, M.D.

    Baqyiattalah University of Medical Science

    STUDY CHAIR
  • S.Ali Ziaee, M.D.

    Erfan Hospital

    PRINCIPAL INVESTIGATOR

Study Design

Study Type
interventional
Phase
phase 4
Allocation
RANDOMIZED
Masking
TRIPLE
Who Masked
PARTICIPANT, CARE PROVIDER, INVESTIGATOR
Purpose
SUPPORTIVE CARE
Intervention Model
PARALLEL
Sponsor Type
OTHER

Study Record Dates

First Submitted

May 12, 2008

First Posted

May 13, 2008

Study Start

August 1, 2007

Primary Completion

December 1, 2007

Study Completion

February 1, 2008

Last Updated

May 13, 2008

Record last verified: 2008-05

Locations